BiologicalDrug
Recombinant factor VIII SQ clinical trials
Also written Xyntha and ReFacto.
How studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 1
Pfizer (7) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · University of Aarhus (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Sinocelltech Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses recombinant factor VIII SQ is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study Evaluating On-Demand Treatment Of Xyntha In Chinese SubjectsCompletedPhase 3PfizerNCT00868530Written as Xyntha
- Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of AgeTerminatedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00759655Written as Moroctocog alfa
- Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A PatientsCompletedPhase 4PfizerNCT04396639Written as Moroctocog-alfa (AF-CC)
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04060836Written as Xyntha
- Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIIICompletedPhase 3PfizerNCT00543439Written as Moroctocog alfa (AF-CC)
- Study Comparing Blood Levels of ReFacto and Advante in Hemophilia AWithdrawnPhase 4Wyeth is now a wholly owned subsidiary of PfizerNCT00168051Written as ReFacto
- Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A PatientsCompletedPhase 4PfizerNCT00914459Written as Moroctocog alfa ( AF-CC)
- Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia AStatus unknownPhase 1Sinocelltech Ltd.NCT02888223Written as Xyntha
- Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care SettingsTerminatedPhase 4PfizerNCT00884390Written as moroctocog alfa (AF-CC) (ReFacto AF)
- Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)CompletedPhase 1PfizerNCT01579903Written as moroctocog alfa (AF-CC)
- Study Evaluating The Safety Of Xyntha In Usual Care SettingsTerminatedPhase 4PfizerNCT00765726Written as Moroctocog alfa(AF-CC)
- Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major SurgeryCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00243659Written as ReFacto AF
- Study Evaluating ReFacto AF in Severe Hemophilia ACompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00037544Written as ReFacto AF
- Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia ACompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00038935Written as ReFacto AF
- Study Evaluating ReFacto® in Hemophilia A Undergoing Major SurgeryCompletedPhase 4Wyeth is now a wholly owned subsidiary of PfizerNCT00092976Written as ReFacto
- Clot Formation and Clot Stability in Patients With Severe Haemophilia ACompletedNot applicableUniversity of AarhusNCT00279578Written as ReFacto (Recombinant factor VIII) and Tranexamic acid
Codes
What other systems call recombinant factor VIII SQ · ClinicalTrials.gg INT004346
- MeSH (NLM) C427184recombinant factor VIII SQOne source NLM
- UNII (FDA) 113E3Z3CJJMOROCTOCOG ALFAConfirmed FDA, NLM
- RxNorm 1300485One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C427184 | recombinant factor VIII SQ | One source NLM |
| UNII (FDA) | 113E3Z3CJJ | MOROCTOCOG ALFA | Confirmed FDA, NLM |
| RxNorm | 1300485 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.